RVMD
New target, same love
Needham decided Revolution Medicines still has room to run, lifting its price target to $186 from $145 while keeping a Buy rating on the name. Translation: the firm’s saying, “Yes, it’s expensive-ish, but we still think the story works.”
Why you should care
When a biotech stock has already doubled, tripled, and then some, every new analyst note gets extra attention. Revolution Medicines has soared 304% over the past year and is trading around $148.63, so this isn’t exactly a sleepy little tweak in a forgotten corner of the market.
The not-so-subtle subtext
Investing.com also flagged the stock as looking overvalued at current levels, which is the classic Wall Street two-step: one hand raises the target, the other waves a tiny caution flag. That’s biotech for you — equal parts moonshot and spreadsheet anxiety.
Big picture
If you own RVMD, this is another reminder that sentiment around the cancer-drug pipeline is still pretty hot. If you don’t, the stock’s huge run means the bar for disappointment is now doing crossfit.